Amylyx price target raised to $28 from $20 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Amylyx (AMLX) to $28 from $20 and keeps a Buy rating on the shares. The firm’s review of the LUCIDITY trial design shows a “structurally de-risked path to approval.” It believes this is being underappreciated by the market.